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Abstract
Introduction
Depression may attenuate the effects of diabetes inter-
ventions.  Our  ongoing  Cardiovascular  Risk  Reduction 
Clinic simultaneously addresses hyperglycemia, hyperten-
sion, smoking, and hyperlipidemia. We examined the rela-
tionship between depression diagnosis and responsiveness 
to the Cardiovascular Risk Reduction Clinic.
Methods
We studied Cardiovascular Risk Reduction Clinic partic-
ipants with diabetes who had a depression diagnosis and 
those with no mental health diagnosis. Our outcome mea-
sure was change in 20-year cardiovascular mortality risk 
according  to  the  United  Kingdom  Prospective  Diabetes 
Study (UKPDS) score.
Results
Of 231 participants, 36 (15.6%) had a depression diagno-
sis. Participants with a depression diagnosis had a higher 
baseline UKPDS score (56.8 [SD 21.3]) than participants 
with no mental health diagnosis (49.5 [SD 18.7], P = .04). 
After Cardiovascular Risk Reduction Clinic participation, 
mean UKPDS scores did not differ significantly (37.8 [SD 
15.9] for no mental health diagnosis and 39.4 [SD 18.6] for 
depression diagnosis). Mean UKPDS score reduction was 
11.6 [SD 15.6] for no mental health diagnosis compared 
with  18.4  [SD  15.9]  for  depression  diagnosis  (P  =  .03). 
Multivariable linear regression that controlled for base-
line creatinine, number of Cardiovascular Risk Reduction 
Clinic visits, sex, and history of congestive heart failure 
showed  significantly  greater  improvement  in  UKPDS 
score among participants with a depression diagnosis (β 
= 6.0, P = .04) and those with more Cardiovascular Risk 
Reduction Clinic visits (β = 2.1, P < .001).
Conclusion
The  Cardiovascular  Risk  Reduction  Clinic  program 
reduced cardiovascular disease risk among patients with 
diabetes  and  a  diagnosis  of  depression.  Further  work 
should  examine  how  depressive  symptom  burden  and 
treatment  modify  the  effect  of  this  collaborative  multi-
factorial  program  and  should  attempt  to  determine  the 
durability of the effect.
Introduction
People with depression and diabetes have more cardio-
vascular  disease  risk  factors  than  people  with  diabetes 
alone  (1).  The  interaction  of  diabetes  and  depression  is 
problematic because each negatively influences the other 
(2). The presence of depression may attenuate the effects 
of diabetes interventions by decreasing patients’ medica-
tion adherence and physical activity and by limiting acqui-
sition  of  diabetes  knowledge  (3-5).  However,  depression 
treatment alone has not been demonstrated to improve 
diabetes outcomes (4,6-8).
The  Cardiovascular  Risk  Reduction  Clinic  (CRRC)  is 
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an  ongoing  clinical  disease  management  program  at 
the  Providence  Veterans  Affairs  (VA)  Medical  Center 
designed for veterans with multiple cardiovascular disease 
risk  factors.  We  use  a  multidisciplinary,  multifactorial 
approach to simultaneously address control of hypergly-
cemia,  hypertension,  smoking,  and  hyperlipidemia.  The 
program  has  been  effective  for  veterans  with  elevated 
cardiovascular disease risk factors at the Providence VA 
Medical Center (9).
We sought to better understand the relationship between 
responsiveness to the CRRC program and depression diag-
nosis. Our hypothesis, based on reports in the literature of 
the impact of depression on diabetes, was that a depres-
sion diagnosis would decrease the effectiveness of the pro-
gram. We used retrospective data from CRRC participants 
to test this hypothesis.
Methods
Study design
We  conducted  a  retrospective  cohort  study  that  was 
approved  by  the  Providence  VA  Medical  Center  insti-
tutional  review  board.  We  obtained  data  for  all  CRRC 
participants enrolled between January 2001 and January 
2002 by record extraction and through review of electronic 
medical  records  for  January  1,  2001,  to  December  31, 
2002. Depression diagnosis (present or not present) was 
determined by the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) coding 
for visits (296.2x, 296.3x, or 311.xx) or mention as a diag-
nosis in the treating clinician’s chart notes. We excluded 
records  that  did  not  have  values  for  body  mass  index, 
serum lipids, hypertension, hemoglobin A1c (HbA1c), or 
smoking status at CRRC baseline. We limited our analysis 
to patients with diabetes. Because we wished to specifically 
examine the impact of a depression diagnosis, we limited 
our scope to patients who had been given a diagnosis of 
depression but no other associated mental health condi-
tion and patients who had no mental health condition at 
all. Therefore, we excluded patients with a diagnosis of 
schizophrenia,  schizoaffective  disorder,  bipolar  disorder 
(type 1 or 2), posttraumatic stress disorder, or generalized 
anxiety disorder, determined from the ICD-9-CM coding 
for visits and from the treating clinician’s chart notes.
Demographic  data  collected  were  age,  sex,  and  race 
(coded  as  white  or  not).  Clinical  data  included  height 
and  weight,  active  medications,  systolic  blood  pressure 
(mm Hg), smoking status (current or not), and history or 
diagnosis of hypertension, stroke, congestive heart failure, 
chronic obstructive pulmonary disease, or coronary artery 
disease (prior myocardial infarction, prior admission for 
unstable angina, coronary artery bypass surgery, or percu-
taneous coronary angioplasty). Laboratory data collected 
were HbA1c (%), fasting total cholesterol (mg/dL), fasting 
high-density  lipoprotein  cholesterol  (HDL,  mg/dL),  fast-
ing low-density lipoprotein cholesterol (LDL, mg/dL), and 
serum creatinine (mg/dL).
We determined antidepressant use during CRRC enroll-
ment by prescription of any of the following medications: 
sertraline, paroxetine, citalopram, fluoxetine, nefazodone, 
venlafaxine, mirtazapine, or amoxapine. The total number 
of CRRC visits was also obtained.
To  avoid  multiple  comparisons,  we  sought  to  use  a 
single,  comprehensive  outcome  measure  applicable  to 
patients with diabetes for cardiovascular disease risk as a 
metric for CRRC effectiveness. We chose to apply the UK 
Prospective Diabetes Study (UKPDS) risk engine (10) for 
20-year risk of cardiac events as that metric. Therefore, 
our outcome measure, the effectiveness of the CRRC, was 
the difference between the baseline UKPDS score and the 
follow-up score.
The elements that go into the UKPDS risk engine are 
age at diagnosis of diabetes, sex, “Afro-Caribbean” race, 
current smoking status, HbA1c, systolic blood pressure, 
and ratio of total cholesterol to HDL. With the exception 
of sex, race, and age at diagnosis of diabetes, all data were 
obtained at baseline and at the time closest to the CRRC 
discharge  date  or  December  31,  2002,  whichever  came 
first. The medical record for the period reviewed did not 
provide information on when diabetes was diagnosed, so 
we assumed an onset age of 55 years for all patients, which 
nullified the age term in the risk calculation.
The Cardiovascular Risk Reduction Clinic
The CRRC was designed to achieve American Diabetes 
Association (ADA) guideline-recommended goals for glyce-
mic control, blood pressure control, lipid control, and smok-
ing cessation using education, behavioral counseling, and 
frequent medication titrations. Clinical pharmacists under 
the supervision of a cardiologist deliver the program. The 
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Belief Model for general behavioral modification counsel-
ing  (11),  the  Fagerstrom  Tolerance  Questionnaire  (12), 
and  the  Transtheoretical  Model  of  readiness  to  change 
for smoking cessation (13). VA clinical pharmacists have 
prescriptive authority to modify medications under their 
scope of practice, and they apply previously formulated 
medication  titration  algorithms  for  cholesterol,  blood 
pressure, smoking, and glycemic control to aggressively 
titrate the medication regimen. A cardiologist is available 
for immediate consultation for difficult management deci-
sions but does not directly provide care to patients enrolled 
in the clinic.
At the initial 30-minute visit, CRRC pharmacists assess 
medication  adherence  and  laboratory  parameters  and 
develop a treatment plan to control hypertension, choles-
terol, and diabetes. Options for smoking cessation are dis-
cussed when applicable. Individualized diet and exercise 
programs are also created, and referral to a nutritionist 
and  physical  therapist  is  made  if  necessary.  Follow-up 
sessions of 30 minutes are scheduled every 6 to 8 weeks 
to  monitor  adherence  and  therapeutic  effects,  reinforce 
lifestyle  modifications,  and  adjust  medications.  Diabetic 
patients are discharged from CRRC once therapeutic goals 
of systolic blood pressure less than 130 mm Hg, HbA1c less 
than 7%, total cholesterol less than 200 mg/dL, and LDL 
cholesterol less than 100 mg/dL are met or nearly met, 
as recommended by the American College of Cardiology/
American Heart Association and ADA guidelines (14-16).
Statistical analysis
For  comparisons  between  the  group  with  no  mental 
health diagnosis and the group with depression diagno-
sis, we used χ2 tests for categorical variables, t tests for 
normally distributed continuous variables, and Wilcoxon 
rank-sum  tests  for  non-normally  distributed  continuous 
variables. The small size of our sample constrained the 
number of variables we could include in the final multi-
variable regression model, so we used Mallows Cp method 
(17) to select the best model in terms of number of covari-
ates and fit.
Results
Of 375 CRRC participants, 231 had either no mental 
health  condition  or  a  depression  diagnosis  as  the  sole 
mental health condition and were therefore included in 
this study. Comparison of the 2 groups (Tables 1 and 2) 
showed  that  patients  with  a  depression  diagnosis  were 
significantly younger, more obese, more likely to be white, 
and more likely to be taking antidepressant medication. 
The difference in median number of CRRC visits was not 
statistically  significant:  4  (interquartile  range  2-6)  for 
patients with a depression diagnosis and 3.5 (interquartile 
range 2-5) for patients without a mental health condition. 
The median time of CRRC enrollment in days also did not 
differ  significantly:  154  (interquartile  range  71-310)  for 
those with a depression diagnosis and 185 (interquartile 
range 72-333) for those without a depression diagnosis. 
No deaths occurred in either group during the period of 
observation. Patients with a depression diagnosis had a 
higher baseline UKPDS score than did patients without 
a mental health condition (P = .047), suggesting a greater 
cardiovascular disease risk.
At the end of the study period, we found no significant 
difference between the mean UKPDS score for the group 
with no mental health diagnosis (37.8 [SD 15.9]) and the 
group with depression diagnosis (39.4 [SD 18.6]). The mean 
change in UKPDS score was 11.6 (SD 15.6) for patients 
with no mental health diagnosis and 18.4 (SD 15.9) for 
patients with a depression diagnosis (P = .03). Baseline 
UKPDS scores were higher for patients with depression 
but discharge scores were similar for both groups.
Using  Mallows  methods  for  our  model  selection,  we 
found  that  the  lowest  Cp  value  was  for  a  5-variable 
model: depression diagnosis, baseline creatinine, number 
of CRRC visits, sex, and history of congestive heart failure. 
The Cp for this model was 0.41, and the r2 value for the 
model was 0.17. In this adjusted model, having a depres-
sion diagnosis was significantly associated with a greater 
improvement in UKPDS score (β = 6.0, P = .04) and greater 
UKPDS score improvement was associated with a higher 
number of CRRC visits (β = 2.1, P < .001). Addition of age 
to the adjusted model did not markedly change the point 
estimate or P value for depression diagnosis.
Discussion
We  found  that  patients  significantly  improved  after 
participation  in  the  CRRC  whether  or  not  they  have  a 
diagnosis  of  depression.  Our  findings  demonstrate  that 
the conventional wisdom regarding the overlap of diabetes 
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and depression is accurate and, more importantly, modi-
fiable. Patients with a depression diagnosis had signifi-
cantly higher cardiovascular disease risk as measured by 
a UKPDS score than did patients with no mental health 
condition, but because they showed greater improvement 
after  participation  in  our  CRRC,  their  cardiovascular 
disease risk at discharge was nearly the same as that of 
patients without a mental health condition. We did not 
observe a difference in number of CRRC visits or duration 
of CRRC enrollment between patients with a depression 
diagnosis and with no mental health diagnosis, suggesting 
that participants with a depression diagnosis do not drop 
out preferentially and do not take longer to achieve CRRC 
goals.  These  findings  demonstrate  that  our  CRRC  pro-
gram is effective in reducing cardiovascular disease risk in 
patients with diabetes regardless of depression diagnosis.
Depression can be underdiagnosed in primary care (18). 
The VA system addresses this problem by conducting an 
annual 2-question screening for depression (19), increasing 
the likelihood of detection. If our focus were on whether a 
depression symptom burden or whether meeting criteria 
for  a  depression  diagnosis  affected  performance  in  the 
CRRC  program,  underdiagnosis  of  depression  would  be 
a concern. However, we were interested in whether car-
rying a depression diagnosis (ie, having been labeled as 
having depression) made a difference in improvement in 
cardiovascular disease risk reduction because we believed 
that providers and patients might be influenced by the 
presence of a depression diagnosis in their management 
of cardiovascular disease risks. Our findings suggest that 
this may be the case; patients with a depression diagnosis 
had  significantly  worse  baseline  cardiovascular  disease 
risk but were able to attain a level of risk similar to that 
of patients without a depression diagnosis on completion 
of the CRRC.
We believe that having a depression diagnosis did not 
attenuate  the  effectiveness  of  the  CRRC  because  the 
CRRC design is supportive. It involves frequent contact 
and  follow-up,  counseling  about  cardiovascular  health, 
and responsiveness to particular patient needs related to 
cardiovascular disease risk. This personal attention may 
counter the negative effects of having a depression diag-
nosis. Another potential benefit is that the CRRC team is 
focused on cardiovascular disease risk reduction and not 
on competing concerns, which may reduce the stigma that 
may  be  associated  with  a  depression  diagnosis.  Lastly, 
activities that are promoted within the program — edu-
cation, healthy diet, and physical activity — may benefit 
both depression, if still present, and cardiovascular dis-
ease risk. However, all of these explanations are specula-
tive, and we do not have supporting data.
Our work has limitations that must be acknowledged. 
Because this was an observational study with a limited 
size, all confounding factors may not have been accounted 
for or included in our model. We relied on a diagnosis of 
depression in the medical record, which may have resulted 
in a misclassification bias, though this would have also 
biased our findings toward the null. We did not have a 
measure of depression severity, so we cannot determine 
whether the diagnosed depression was active or in remis-
sion. We do not know whether depressive symptom burden 
or antidepressant medication use changed over the course 
of  participation  in  the  CRRC  nor  how  this  would  have 
affected our findings. Although we hoped to also examine 
the impact of depression treatment, most patients with 
a  depression  diagnosis  were  receiving  antidepressants, 
which also raises the question of whether we are seeing 
the effect of depression treatment within this group. One 
might take the magnitude of improvement of patients with 
depression compared to that of patients without depres-
sion as regression to the mean (ie, less improvement was 
seen in those without depression because they had less 
room for improvement). However, it is not the magnitude 
of improvement that is the point of interest but that those 
with a depression diagnosis had greater risk before the 
CRRC and improved to a level similar to that of patients 
without a depression diagnosis on completion of the CRRC 
program.  We  must  acknowledge  that  the  utility  of  the 
UKPDS risk engine for change over time has not been 
validated. However, individual outcome measures proven 
to predict cardiovascular disease risk were all improved 
after  the  intervention,  so  the  global  score  was  a  good 
summary  of  the  overall  improvement  in  cardiovascular 
disease  risk.  Lastly,  our  population  was  predominantly 
male veterans in a closed health care system, which limits 
generalizability.
Our  findings  demonstrate  that  a  multifactorial  car-
diovascular  disease  risk  reduction  clinic  run  by  clinical 
pharmacists was effective in veterans with diabetes and 
a  depression  diagnosis.  Furthermore,  having  a  depres-
sion diagnosis was associated with greater cardiovascular 
disease risk before participation in the clinic. Our work 
indicates that having a depression diagnosis should not be 
considered a barrier to referral or participation in such a 
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high-risk patients. Further research is necessary to under-
stand the mediating effects of depressive symptom burden 
and of depression treatment on the effectiveness of multi-
factorial cardiovascular disease risk reduction programs 
and on the durability of the effect we observed.
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Tables
Table 1. Baseline Population Characteristics by Depression Diagnosis, Cardiovascular Risk Reduction Clinic Participants, 
2001-2002
Characteristic
No Mental Health Diagnosis  
N = 195
Depression Diagnosis  
N = 36 P value
Mean age, y (SD) 68.8 (9.5) 62.9 (11.2) .001a
Female, % 1.5 2.8 .60b
White, % 9.0 58. .0b
Tobacco use, % 2.6 27.8 .59b
BMI, kg/m2 (SD) 0. (5.0) .0 (8.7) .009a
Creatinine, mg/dL (SD) 1.4 (0.8) 1.6 (1.4) .9a
On antidepressant medication, % 15.4 72.2 <.001b
Coronary artery disease, % 4.6 41.7 .8b
Stroke, % 6.7 19.4 .01b
Congestive heart failure, % 21.5 16.7 .52b
COPD, % 18.0 8. .15b
 
Abbreviations: SD, standard deviation; BMI, body mass index; COPD, chronic obstructive pulmonary disease.  
a P values are for the t test. 
b P values are for the χ2 test.Table 2. Cardiovascular Disease Risk Factors at CRRC Baseline and After CRRC Participation by Depression Diagnosis, 2001-
2002
Cardiovascular Risk
No Mental Health Diagnosis Depression Diagnosis
Baseline 
N = 188
Follow-Up 
N = 180
Changea 
N = 176
Baseline 
N = 39
Follow-Up 
N = 29
Changea 
N = 28
HbA1c, % (SD) 8.4 (2.0) 7.4 (1.4) 1.1 (1.8) 8.9 (2.2) 8.0 (2.) 1.1 (2.0)
LDL, mg/dL (SD) 106.0 (.0) 9.9 (28.8) 11.6 (1.9) 114.7 (1.) 91.8 (7.6) 21.8 (40.8)
Total cholesterol, mg/dL (SD) 184.5 (4.5) 167.2 (9.) 18.2 (41.8) 195.9 (8.5) 172.5 (4.7) 28.5 (48.9)
Systolic blood pressure, mm Hg (SD) 15.0 (16.7) 128.9 (12.8) 6.1 (16.6) 16.6 (14.7) 12.6 (12.) 12.6 (1.4)
UKPDS score, (SD)b 49.5 (18.7) 7.8 (15.9) 11.6 (15.6) 56.8 (21.) 9.4 (18.6) 18.4 (15.9)
HDL, mg/dL (SD) 9.4 (11.1) 9.1 (10.9) 0.5 (6.1) 7.9 (8.4) 41.2 (11.1) -2.6 (12.8)
Body mass index, kg/m2 (SD) 0. (5.0) 0. (5.0) -0.06 (1.4) .0 (8.7) .2 (9.1) -0. (1.6)
Tobacco use, % 2.6 14.9 8.7 27.8 25 2.8
 
Abbreviations: CRRC, Cardiovascular Risk Reduction Clinic; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein cholesterol; UKPDS, United Kingdom 
Prospective Diabetes Study; HDL, high-density lipoprotein cholesterol. 
aChange scores are presented only for patients who had both baseline and follow-up scores. Numbers do not total 21 because not all patients had a 
UKPDS score. 
bUKPDS score rates the probability of 20-year cardiovascular mortality.
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